VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 93 filers reported holding VERVE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 4.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $335,717 | -26.7% | 25,318 | +3.7% | 0.00% | -33.3% |
| Q2 2023 | $457,838 | +40.7% | 24,418 | +8.2% | 0.00% | +50.0% |
| Q1 2023 | $325,431 | -24.0% | 22,568 | +2.0% | 0.00% | -33.3% |
| Q4 2022 | $428,003 | -42.3% | 22,119 | +2.4% | 0.00% | -40.0% |
| Q3 2022 | $742,000 | +181.1% | 21,601 | +24.9% | 0.01% | +150.0% |
| Q2 2022 | $264,000 | -36.1% | 17,288 | -4.5% | 0.00% | 0.0% |
| Q1 2022 | $413,000 | +33.2% | 18,095 | +115.5% | 0.00% | 0.0% |
| Q4 2021 | $310,000 | -23.6% | 8,397 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $406,000 | – | 8,648 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |